Efficacy and safety of hepatic arterial infusion chemotherapy combined with palliative transarterial chemoembolization followed by targeted therapy and immunotherapy in patients with BCLC stage C hepatocellular carcinoma: Clinical trial protocol

Background Interventional therapy combined with systemic treatment has demonstrated promising antitumor activity and an overall manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma (HCC). However, prospective evidence supporting the optimal combination strategy remains limited, and the tumor immune microenvironment (TIME) characteristics underlying differential treatment responses have not been systematically elucidated. The present study aims to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with palliative transarterial chemoembolization (TACE), followed by sequential targeted-immunotherapy, in treatment-naïve patients with BCLC stage C HCC, while also exploring the TIME features associated with therapeutic response. Methods This study is a prospective, single-arm, phase II clinical trial that will enroll treatment-naïve patients with BCLC C HCC who are unsuitable for surgical resection. Tumor tissue and peripheral blood samples will be collected at baseline prior to treatment initiation. All patients will receive HAIC with a modified FOLFOX regimen combined with palliative TACE. Immediately after the interventional procedure, patients will undergo intra-arterial infusion of bevacizumab (200–300 mg) and intravenous administration of sintilimab (200 mg) every three weeks for a total of six cycles. After two treatment cycles, patients will be stratified according to their treatment response, and five additional tumor tissue and blood samples will be collected from each group. Upon completion of local therapy, patients will continue with maintenance therapy consisting of intravenous bevacizumab (15 mg/kg) and sintilimab (200 mg) every three weeks until disease progression or the development of intolerable toxicity. Discussion This study will evaluate the efficacy and safety of HAIC combined with palliative TACE followed by sequential targeted-immunotherapy and explore TIME features associated with treatment response. The findings may provide evidence to inform multimodal treatment strategies and personalized therapy for advanced HCC. Trial registration number ChiCTR2500115704

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-19
DOI
https://doi.org/10.1371/journal.pone.0363254
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of hepatic arterial infusion chemotherapy combined with palliative transarterial chemoembolization followed by targeted therapy and immunotherapy in patients with BCLC stage C hepatocellular carcinoma: Clinical trial protocol

Yang Fang, Songnan Zhang
PLoS ONE
Hepatocellular Carcinoma Treatment and Prognosis
article

Efficacy and safety of hepatic arterial infusion chemotherapy combined with palliative transarterial chemoembolization followed by targeted therapy and immunotherapy in patients with BCLC stage C hepatocellular carcinoma: Clinical trial protocol

Yang Fang, Songnan Zhang
article en

Abstract

Background Interventional therapy combined with systemic treatment has demonstrated promising antitumor activity and an overall manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma (HCC). However, prospective evidence supporting the optimal combination strategy remains limited, and the tumor immune microenvironment (TIME) characteristics underlying differential treatment responses have not been systematically elucidated. The present study aims to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with palliative transarterial chemoembolization (TACE), followed by sequential targeted-immunotherapy, in treatment-naïve patients with BCLC stage C HCC, while also exploring the TIME features associated with therapeutic response. Methods This study is a prospective, single-arm, phase II clinical trial that will enroll treatment-naïve patients with BCLC C HCC who are unsuitable for surgical resection. Tumor tissue and peripheral blood samples will be collected at baseline prior to treatment initiation. All patients will receive HAIC with a modified FOLFOX regimen combined with palliative TACE. Immediately after the interventional procedure, patients will undergo intra-arterial infusion of bevacizumab (200–300 mg) and intravenous administration of sintilimab (200 mg) every three weeks for a total of six cycles. After two treatment cycles, patients will be stratified according to their treatment response, and five additional tumor tissue and blood samples will be collected from each group. Upon completion of local therapy, patients will continue with maintenance therapy consisting of intravenous bevacizumab (15 mg/kg) and sintilimab (200 mg) every three weeks until disease progression or the development of intolerable toxicity. Discussion This study will evaluate the efficacy and safety of HAIC combined with palliative TACE followed by sequential targeted-immunotherapy and explore TIME features associated with treatment response. The findings may provide evidence to inform multimodal treatment strategies and personalized therapy for advanced HCC. Trial registration number ChiCTR2500115704

PLoS ONEVol. 21(11)
Yanbian University Hospital (CN)
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon